Clinical Trials Browser

Completed × INDUSTRY × duvelisib × Clear all

NCT03372057 2025-03-07

PRIMO

Phase 2 Completed

156 enrolled 21 charts

Lymphoma, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Phase 3 Completed

319 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02049515 2023-09-21

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Phase 3 Completed

99 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02711852 2023-09-11

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Phase 2 Completed

19 enrolled 11 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT02598570 2017-02-06

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Phase 1 Completed

Lymphoma, Hereditary Sensory and Autonomic Neuropathies